39
Participants
Start Date
November 1, 2024
Primary Completion Date
November 1, 2026
Study Completion Date
March 1, 2027
Orelabrutinib Oral Tablet
Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
R-CHOP Protocol
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
RECRUITING
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou
RECRUITING
Dongguan People's Hospital, Dongguan
RECRUITING
Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou
RECRUITING
Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai
RECRUITING
Gansu Cancer Hospital, Lanzhou
RECRUITING
First People's Hospital of Guangzhou, Guangzhou
RECRUITING
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou
RECRUITING
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
RECRUITING
First Affiliated Hospital of Shantou University Medical College., Shantou
RECRUITING
Shenzhen People's Hospital, Shenzhen
RECRUITING
Zhaoqing First People's Hospital, Zhaoqing
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Gansu Cancer Hospital
OTHER
First Affiliated Hospital of Shantou University Medical College
OTHER
Southern Medical University, China
OTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
Fifth Affiliated Hospital of Guangzhou Medical University
OTHER
Shenzhen People's Hospital
OTHER
Guangzhou First People's Hospital
OTHER
Dongguan People's Hospital
OTHER_GOV
The First People's Hospital of Zhaoqing
UNKNOWN
Sun Yat-sen University
OTHER